Geode Capital Management’s Vigil Neuroscience VIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-304,071
| Closed | -$2.42M | – | 4569 |
|
|
2025
Q2 | $2.42M | Buy |
304,071
+59,537
| +24% | +$267K | ﹤0.01% | 3079 |
|
|
2025
Q1 | $435K | Buy |
244,534
+16,010
| +7% | +$35.9K | ﹤0.01% | 3597 |
|
|
2024
Q4 | $389K | Buy |
228,524
+2,441
| +1% | +$7.21K | ﹤0.01% | 3687 |
|
|
2024
Q3 | $769K | Buy |
226,083
+66,712
| +42% | +$247K | ﹤0.01% | 3447 |
|
|
2024
Q2 | $638K | Sell |
159,371
-174,871
| -52% | -$598K | ﹤0.01% | 3483 |
|
|
2024
Q1 | $1.14M | Buy |
334,242
+18,704
| +6% | +$58.4K | ﹤0.01% | 3324 |
|
|
2023
Q4 | $1.07M | Buy |
315,538
+10,363
| +3% | +$53.3K | ﹤0.01% | 3335 |
|
|
2023
Q3 | $1.65M | Buy |
305,175
+20,332
| +7% | +$140K | ﹤0.01% | 3139 |
|
|
2023
Q2 | $2.68M | Buy |
284,843
+172,451
| +153% | +$1.63M | ﹤0.01% | 3019 |
|
|
2023
Q1 | $1.1M | Buy |
112,392
+8,625
| +8% | +$97K | ﹤0.01% | 3304 |
|
|
2022
Q4 | $1.3M | Buy |
103,767
+31,948
| +44% | +$392K | ﹤0.01% | 3237 |
|
|
2022
Q3 | $653K | Buy |
71,819
+12,174
| +20% | +$89.3K | ﹤0.01% | 3594 |
|
|
2022
Q2 | $153K | Sell |
59,645
-37,435
| -39% | -$148K | ﹤0.01% | 4406 |
|
|
2022
Q1 | $682K | Buy |
+97,080
| New | +$1.28M | ﹤0.01% | 3788 |
|
Other funds holding VIGL
Geode Capital Management's VIGL Position: Q3 2025 in Review
Geode Capital Management sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 304,071 shares — an estimated $2.42M sold.
Geode Capital Management first reported a position in VIGL in Q1 2022 and held it in 14 quarters. The position peaked at $2.68M in Q2 2023. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.
- Geode Capital Management reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
- Geode Capital Management sold 304,071 Vigil Neuroscience shares in Q3 2025, an estimated $2.42M.
- Geode Capital Management first reported a position in Vigil Neuroscience in Q1 2022 and held it in 14 quarters.
- Geode Capital Management's Vigil Neuroscience position peaked at $2.68M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.
Based on Geode Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.